Sirion Therapeutics Initiates Two Phase III Clinical Trials

Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceutical company, announced today that it has initiated new phase III clinical programs for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

TAMPA, FL, USA | May 1, 2007 | Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceutical company, announced today that it has initiated new phase III clinical programs for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

The two new clinical programs are designed to evaluate ST-601 (difluprednate) as a potential therapy for the treatment of anterior uveitis and ST-603 (cyclosporine) as a potential therapy for the treatment of dry eye syndrome. The addition of these clinical programs brings the company's active clinical programs to five. Sirion's aim is to provide a diverse product offering for the treatment of debilitating ophthalmic diseases and conditions.

Dr. Roger Vogel, Sirion's Chief Medical Officer, commented, "We are pleased with the progress we have made in all of our clinical programs. We have built an excellent network of experienced and professional clinical investigators that have afforded us our success to date."

"I am proud of the hard work and innovative spirit of our R&D staff," said Barry Butler, Sirion's President and Chief Executive Officer. "Our clinical and regulatory teams have done an outstanding job with the planning and execution of our development programs to date."

About Sirion Therapeutics, Inc.

Sirion Therapeutics is an ophthalmic biopharmaceutical company poised to compete in the $4 billion U.S. prescription ophthalmic market segment. Sirion is dedicated to the development and commercialization of innovative products to address unmet clinical needs. The company has raised $75 million to date and is currently developing a portfolio of product candidates that includes therapies in the areas of inflammatory diseases and conditions, allergy, dry eye, herpetic keratitis and dry age-related macular degeneration. Sirion is focused on growth through in-licensing, acquisition and geographic expansion. For more information regarding Sirion, please visit Sirion's website at http://www.siriontherapeutics.com/.


SOURCE: Sirion Therapeutics, Inc.

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top